Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
REPLthis companyReplimune Group, Inc.	$22.17	-2.26×	4.27×	0×	-2.03×	-94.9%	0.0%	0.0%	0.0%	-188.9%	-114.8%	-40.1%	0.67×	0.32×	-36.11×	4.79×	0.0%	2	-0.08	1	C-
AGENAgenus Inc.	$7.55	-923.53×	-0.34×	0.82×	6.84×	-468.1%	29.6%	-18.0%	0.1%	-0.0%	-34.5%	-170.2%	-1.24×	5.34×	-0.37×	0.41×	0.0%	6	-14.32	2	C+
CTMXCytomX Therapeutics, Inc.	$2.12	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
IBRXImmunityBio, Inc.	$7.00	-5.21×	-3.65×	16.08×	-11.68×	-355.9%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	3	-10.89	2	C
IOVAIovance Biotherapeutics, Inc.	$8.54	-2.5×	1.4×	3.7×	-2.45×	-50.5%	34.3%	-151.1%	-148.4%	-56.0%	-50.9%	-34.5%	0.07×	0.33×	0×	3.2×	0.0%	4	7.46	2	C
JANXJanux Therapeutics, Inc.	$14.14	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
Peer median	—	-7.54×	0.89×	7.71×	-7.39×	-283.4%	79.7%	-151.1%	-148.4%	-11.9%	-34.5%	-17.0%	0.02×	0.33×	0×	3.2×	0.0%	3	1.34	2	—